Bookmark

Media centre

Press releases

To be notified when a new press release is added to this site please register with our alert service.

Date	Title
16/12/2009	AS1411 shows activity in kidney cancer but AML remains priority
09/12/2009	ASA404 to feature in Novartis Oncology Pipeline Update and at San Antonio Breast Cancer Symposium
07/12/2009	AS1413 regimen yields high response rate and durable responses in patients with secondary AML, a poor-risk population underserved by current treatment options
25/11/2009	Antisoma to present at Piper Jaffray Health Care Conference
10/11/2009	Antisoma AGM update and Interim Management Statement
13/10/2009	Antisoma's AS1411 gains US and EU Orphan Drug Status for acute myeloid leukaemia
09/10/2009	Annual Report and Accounts 2009
08/10/2009	Antisoma to amend ACCEDE phase III study of AS1413
18/09/2009	Antisoma to present at the UBS Global Life Sciences Conference in New York
16/09/2009	Antisoma to present at the Bank of America Merrill Lynch Global Healthcare Conference in London
14/09/2009	Antisoma’s preliminary results for the year ended 30 June 2009
03/09/2009	Antisoma to present at the Rodman & Renshaw Healthcare Conference in New York
01/09/2009	Phase III trial of ASA404 in lung cancer completes patient enrolment
11/08/2009	Antisoma and Bryan Oncor announce deal for anti-cancer drug P2045
07/08/2009	Antisoma announces discontinuation of development of AS1402
05/08/2009	Antisoma to present at the Canaccord Adams 29th Annual Global Growth Conference in Boston
18/06/2009	Antisoma to present at Piper Jaffray Europe Conference in London
15/06/2009	Antisoma to present at 3rd Annual Jefferies Healthcare Conference in New York
05/06/2009	Antisoma to present at 8th Annual Needham Life Sciences Conference in New York
31/05/2009	Antisoma’s AS1409 shows anti-cancer activity in phase I trial
Page 1 2 >>